RxDoctor Payments Data

Aman Kakkar, MD

Cardiovascular Disease · Cumming, GANPI 1801833173

Payments from drug & device makers

$6,906in general payments, 2019–2025

Across 308 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$822
  • Pfizer$702
  • Biotronik Inc.$556
  • Boston Scientific$553
  • Novartis$505
  • Medtronic$340
  • plus $3K from 42 others

What the payments were for

  • Travel & lodging$4406%
  • Food & beverage$6,36792%
  • Education$330%
  • Entertainment$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,906 in reported general payments places this provider in the 75th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$1,085,095
Medicare patients
1,735
Services billed
7,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban722$726,604
XareltoRivaroxaban293$318,376
EntrestoSacubitril/Valsartan134$159,512
Repatha SureclickEvolocumab74$66,642
NexlizetBempedoic Acid/Ezetimibe37$15,558
Dabigatran EtexilateDabigatran Etexilate Mesylate36$13,728
Ranolazine ErRanolazine87$13,119
FarxigaDapagliflozin Propanediol15$11,960
Rosuvastatin Calcium669$8,381
Metoprolol Succinate705$8,379
Carvedilol924$8,151
Olmesartan Medoxomil454$7,110
Flecainide Acetate142$6,838
Diltiazem 24hr Er (Cd)Diltiazem Hcl192$6,299
Ezetimibe279$6,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$702$726,604722 claims
Johnson & JohnsonXarelto$822$318,376293 claims
NovartisEntresto$505$159,512134 claims
Esperion Therapeutics, Inc.Nexlizet$129$15,55837 claims
AstraZenecaFarxiga$105$11,96015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →